BridgeMD
New treatment option for Metastatic Renal Cell Carcinoma ( mRCC)
Official title Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
ClinicalTrials.gov ID: NCT06601296
What this study is testing
What is IMSA101?
IMSA101 is an investigational medicine, given as a monthly injectable medicine, being studied as a potential treatment for metastatic renal cell carcinoma ( mrcc).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must have metastatic ccRCC.
- Patients must have oligoprogression defined as progression in ≤5 lesions.
- All oligoprogression lesions must be suitable for radiation.
- Patients must have at least one site of disease that can be safely injected with IMSA101.
- Karnofsky Performance Status (KPS) of at least 50%.
You likely can't join if
- Patients with progressive ultracentral/central chest lesions will be excluded
See the full eligibility criteria
- Patients must have metastatic ccRCC.
- Patients must have oligoprogression defined as progression in ≤5 lesions.
- All oligoprogression lesions must be suitable for radiation.
- Patients must have at least one site of disease that can be safely injected with IMSA101.
- Karnofsky Performance Status (KPS) of at least 50%.
- Age ≥ 18 years.
- Patients must have adequate organ and marrow function within 14 days prior to study entry.
- All IMDC risk categories are allowed.
- Patients with progressive ultracentral/central chest lesions will be excluded
The study team makes the final eligibility decision.
Where it's taking place
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dallas, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.